Product logins

Find logins to all Clarivate products below.


Focal Segmental Glomerulosclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Focal Segmental Glomerulosclerosis (US)

Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which scarring occurs to the glomeruli. Although no drug therapies are approved for FSGS, physicians often prescribe RAAS inhibitors off-label to reduce proteinuria, and diuretics are commonly used to treat symptoms. Corticosteroid and immunosuppressive therapies are also considered for FSGS associated with clinical features of the nephrotic syndrome. However, owing to FSGS’s various etiologies and differences in presentation, management of the disease must be individualized. This report examines how key current therapies are being used to treat newly diagnosed and recently treated FSGS patients.

Questions answered

  • What patient shares do key therapies garner by line of therapy in newly diagnosed FSGS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed FSGS patients?
  • How are corticosteroids integrated into the treatment algorithm, and what is their source of business?
  • What percentage of FSGS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of FSGS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States.

Key drugs: Alkylating agents, corticosteroids, diuretics, RAAS inhibitors.

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…